2,400+ researchers supplied
99+ COAs published
6-panel tested every lot
Processing within 1–3 business days
FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150Cardiogen is a short tetrapeptide (H-Ala-Glu-Asp-Arg-OH, also abbreviated as ADER) derived from cardiac tissue and belongs to a class of peptides developed to support organ-specific regulation.
Studied initially in Eastern Europe, Cardiogen is designed to interact with cardiomyocytes and the cardiac conduction system, where it may influence gene expression linked to cell survival, protein synthesis, and myocardial repair [1].
Its peptide sequence allows it to function as a signaling molecule, potentially modulating various cellular pathways involved in cardiac metabolism and structural integrity.
As there is no clinical study on the Cardiogen peptide to date, it remains a research compound without approved therapeutic use. Cardiogen remains under investigation for its potential role in supporting heart cell homeostasis.
Cardiogen may support cardiomyocyte survival by maintaining structural and functional stability in cells exposed to stress.
Although the precise molecular mechanisms remain under investigation, experimental reports suggest that Cardiogen may modulate pathways involved in apoptosis [2].
Rather than acting as a direct inhibitor, Cardiogen could influence cellular homeostasis, potentially helping reduce premature loss of cardiac cells.
In a rat model of myocardial infarction (MI), administration of Cardiogen resulted in a three-fold reduction in mortality, reduced necrotic heart tissue, and preserved glycogen reserves [3].
These findings suggest that Cardiogen preserves and protects cardiac tissue by stabilizing mitochondrial integrity and modulating apoptosis.
Cardiogen has been studied for its potential to stimulate cardiomyocyte proliferation and enhance reparative biosynthesis, including the upregulation of anti-apoptotic factors necessary for tissue recovery.
An animal study extracted myocardial tissue explants from young (three-month-old) and aged (24-month-old) rats to evaluate the effect of Cardiogen and other amino acids on cell proliferation and apoptosis regulation [4].
After tissue exposure to 20 individual amino acids or to the synthetic tetrapeptide Cardiogen, all substances were tested at a concentration of 10⁻¹² M.
Among the 20 amino acids tested, 7 stimulated cell proliferation in young rats, while only 2 amino acids had any proliferative effect in aged rats.
However, Cardiogen demonstrated the strongest effect by:
This study demonstrates that Cardiogen exhibits pro-proliferative and anti-apoptotic effects in myocardial tissue from both young and aged rats at extremely low concentrations.
One mechanism proposed for Cardiogen is its modulation of extracellular matrix (ECM) remodeling. Following cardiac injury, excessive deposition of collagen and matrix proteins can lead to fibrosis, reducing myocardial elasticity and impairing contractile function [5]. If Cardiogen can help regulate fibroblast activity by balancing collagen synthesis and degradation, this may help preserve normal heart function after cardiac injury.
Beyond its relevance to cardiology research, Cardiogen has also been evaluated in experimental oncology for its potential effects on cell differentiation and gene regulation.
A preclinical in vivo study evaluated the effect of Cardiogen peptide on tumor growth in 78 aged rats implanted with M-1 sarcoma, a fast-growing connective tissue tumor [2].
Rats were divided into five total groups:
Results showed:
Cardiogen may help restore regulatory signals in dysplastic or malignant cells, potentially promoting a shift toward more normalized cellular behavior.
Further research is needed to clarify the molecular mechanisms behind these observations.
Cardiogen’s structure suggests that it may help maintain metabolic stability in cardiac cells, particularly under conditions of stress or aging.
Pro-proliferative effects may occur via DNA and RNA synthesis, a process essential for sustaining protein turnover and cellular maintenance.
This activity may indirectly support mitochondrial function by promoting the renewal of metabolic enzymes and structural proteins required for cardiac energy metabolism.
Although direct effects on ATP production have not been formally established, Cardiogen may contribute to overall energetic resilience in cardiomyocytes.
Further research is needed to clarify whether Cardiogen directly influences mitochondrial activity, oxidative phosphorylation, or glycogen storage.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). Cardiogen is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes six independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 6-panel testing protocol: identification by ESI-MS, purification by RP-HPLC, conformity, sterility screening, quantification of net peptide content, and LAL endotoxin screening. Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders are processed within 1–3 business days after payment confirmation. Orders placed after 3:00 PM Pacific time or on weekends and holidays will begin processing the next business day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and quantification data where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 100+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.
What is CJC 1295 without DAC? CJC-1295 without DAC (Drug Affinity Complex) is a synthetic peptide analogue of growth hormone–releasing hormone (GHRH) designed to enhance pulsatile growth hormone (GH) secretion [1]. CJC-1295 is a modified 30-amino-acid fragment of native GHRH that incorporates substitutions at positions 2, 8, 15, and 27, to increase stability. Because GH secretion is tightly rhythm-regulated, particularly during sleep, preserving this pulsatile pattern can support metabolic, muscular, and regenerative functions. CJC 1295 mechanism of actions and health benefits GH/IGF secretagogue Because GH secretion naturally occurs in rhythmic bursts, especially during deep sleep, CJC-1295 without DAC preserves this pattern rather than producing continuous elevation [2]. Once GH is released, it stimulates hepatic and peripheral production of insulin-like growth factor-1 (IGF-1). IGF-1 mediates many of GH’s downstream actions, including [3]: Muscle protein synthesis Connective tissue repair Metabolic regulation By amplifying both GH and IGF-1 signaling, CJC-1295 without DAC acts as a dual-phase secretagogue. Two randomized, double-blind, placebo-controlled dose ascending trials of healthy adults (over 28 and 49 days, respectively), characterized the profile of CJC-1295 [4]. In the first trial, participants received one of four ascending single subcutaneous doses of CJC-1295 or placebo. In the second trial, participants received two or three weekly or biweekly injections. Results showed that: A single-dose administration induced dose-dependent increases in mean plasma GH, ranging from 2 to 10-fold above baseline Mean plasma IGF-1 increased 1.5 to 3-fold after a single subcutaneous injection, lasting 9–11 days. With multiple dosing, IGF-1 remained consistently above baseline for up to 28 days No serious adverse events or trial withdrawal were reported across either study. Improved body composition CJC-1295 without DAC amplifies natural pulsatile GH release, creating a metabolic environment that supports gradual, physiologic recomposition. Key mechanisms underlying these effects include [5]: Increased Lipolysis Improved Lean Mass Retention Preservation of Metabolic Rate A GHRH gene–ablated (GHRHKO) mice was studied to determine whether CJC-1295 can normalize growth and body composition in the absence of endogenous GHRH [5]. Over 5 weeks, mice were split into the following treatment groups: CJC-1295 2 µg every 24 hours CJC-1295 2 µg every 48 hours CJC-1295 2 µg every 72 hours Placebo-treated GHRHKO mice (control) Heterozygous littermates (normal growth reference) Results showed that: Daily CJC-1295 (24h interval) fully normalized body weight and body length, matching heterozygous controls. 48h or 72h dosing significantly improved growth but did not fully normalize it. Femur and tibia lengths were normal with daily or 48h dosing. 72h dosing did not fully normalize skeletal measures. All regimens preserved normal relative lean mass and subcutaneous fat mass. Increased total pituitary RNA and elevated GH mRNA expression This study highlights the therapeutic potential of CJC-1295 in severe GHRH deficiency and underscores the importance of dosing frequency in achieving full physiologic restoration. Injury recovery CJC-1295 without DAC may support tissue repair and recovery from musculoskeletal injury through its influence on growth hormone–mediated regenerative pathways [6]. Because GH and IGF-1 play roles in: Collagen turnover Tendon integrity Cellular repair enhancing their natural pulsatile release can create a biochemical environment favorable for healing. Key mechanisms underlying these effects include: Enhanced collagen synthesis Improved soft-tissue repair Support for bone and cartilage health Reduced downtime after physical stress Currently, no robust studies exist that investigate these potential effects. Advantages and disadvantages of CJC 1295 without DAC CJC-1295 without DAC offers a distinct therapeutic profile shaped by its shorter half-life and physiologic mimicry of natural growth hormone secretion. Advantages Mimics Natural GH Physiology Because CJC-1295 without DAC delivers pulsatile GH stimulation, this can reduce the risk of GH receptor desensitization. Lower Risk of Side Effects Pulsatile secretagogues tend to cause fewer adverse effects such as: Fluid retention Numbness Insulin resistance The intermittent stimulation gives metabolic pathways time to normalize between pulses. Better Control Over Timing Users and clinicians can schedule injections around sleep cycles, fasting windows, or training sessions to optimize GH peaks. Disadvantages Requires More Frequent Injections Because the peptide is rapidly cleared, achieving meaningful GH pulses may require one to three injections daily. This can reduce convenience and adherence compared to once-weekly DAC formulations. Shorter Therapeutic Window Missed doses or inconsistent scheduling can significantly affect outcomes, as the peptide’s benefits depend on steady, rhythmic stimulation.
What is CJC 1295 with DAC? CJC-1295 with DAC (Drug Affinity Complex) is a long-acting synthetic analogue of growth hormone–releasing hormone (GHRH) engineered to extend the duration of pulsatile growth hormone (GH) stimulation [1]. While short-acting GHRH analogues mimic the body’s natural rhythm in brief intervals, the DAC modification enables CJC-1295 to bind covalently to circulating albumin, dramatically increasing its half-life and sustaining its physiologic influence for days rather than hours [2]. This stability allows for consistent signaling through the GH–IGF-1 axis, which plays a central role in growth, tissue maintenance, and metabolic regulation [3]. This 30 amino acid peptide retains features of native GHRH but incorporates amino-acid substitutions that enhance resistance to enzymatic breakdown. When combined with DAC, these modifications create a formulation capable of maintaining elevated IGF-1 levels with infrequent administration. CJC-1295 can provide extended support to endocrine pathways involved in cellular repair, lean-mass maintenance, and metabolic homeostasis. CJC 1295 with DAC benefits and advantages Prolonged elevation of GH and IGF-1 The DAC modification helps the peptide to form a stable covalent bond with serum albumin, significantly prolonging its half-life compared to non-DAC formulations. This prolonged activity allows for more sustained elevations in circulating IGF-1, a key mediator of anabolic and metabolic processes. IGF-1 plays essential roles in protein synthesis, cellular repair, mitochondrial function, and nutrient partitioning. By maintaining higher IGF-1 concentrations over several days, CJC-1295 with DAC provides a longer, smoother signaling window that may enhance the body’s ability to support tissue maintenance and energy balance. While short-acting GHRH analogues rely on frequent dosing to achieve measurable changes, the DAC-bound version generates a more gradual and durable physiological response. This extended profile can: Reduce fluctuations Minimize peaks and troughs While preserving the rhythmic qualities of GH secretion and broadening the duration of downstream effects. An interventional clinical study of healthy adult men evaluated the effects of CJC-1295 on GH secretion parameters [4]. Participants received either 60 μg/kg or 90 μg/kg of a single subcutaneous injection of CJC-1295 with DAC. Participants then underwent 20-minute interval blood sampling over 12 hours overnight to characterize GH pulsatility. Results showed that: GH Secretion Increased without disrupting pulsatility Basal GH increased 7.5-fold (p < 0.0001) Mean GH levels increased by 46% (p < 0.01) IGF-1 IGF-1 levels increased by 45% (p < 0.001) 60 μg/kg vs 90 μg/kg showed no significant difference in GH or IGF-1 effects. A single dose of CJC-1295 significantly increases basal (trough) GH secretion, leading to higher mean GH and IGF-1 levels, while keeping pulsatility intact. Body composition and muscle growth benefits CJC-1295 with DAC’s extended influence on the GH–IGF-1 axis can create a metabolic and anabolic environment that supports favorable shifts in body composition. Growth hormone plays a central role in nutrient partitioning, encouraging the body to utilize fat as an energy substrate while preserving lean tissue. Through its prolonged stimulation of GH release and sustained elevation of IGF-1, CJC-1295 with DAC can reinforce pathways associated with [5]: Muscle protein synthesis Connective-tissue turnover Recovery from mechanical stress IGF-1 is particularly significant in this context, as it is involved in regulating: Satellite cell activation [6] Collagen formation [7] Structural remodeling within muscle fibers By maintaining more consistent IGF-1 levels over time, CJC-1295 with DAC may help the body support muscle maintenance and gradual increases in lean mass, especially when combined with resistance training or periods of heightened physical demand. Currently however, no human trials exist that evaluate these potential effects. A previous study did attempt to characterize whether CJC 1295 can reduce visceral fat in HIV patients with pathologic lipodystrophy [8]. However, after the death of a participant due to HIV itself, the trial was discontinued, with no data published. Although there is some volume of anecdotal evidence of online users self-administering CJC 1295 for weight loss, regulated human studies need to be established to validate these theoretical applications.
